1. Introduction {#sec1-ijerph-13-00882}
===============

Composite ischemic cardiovascular disease (CVD), including coronary artery disease (CAD), ischemic stroke (IS), and myocardial infarction (MI) has become a serious public health problem around the world because of their high morbidity and mortality \[[@B1-ijerph-13-00882],[@B2-ijerph-13-00882]\]. However, their exact mechanisms are still unclear. For a long time, atherosclerosis (AS) has attracted attention because it is the pathological foundation of CAD, IS, and MI. Abnormal cholesterol metabolism was considered to be the main factor for atherosclerosis, and epidemiological evidence considered low concentrations of serum high-density lipoprotein cholesterol (HDL-C) to be an independent risk factor \[[@B3-ijerph-13-00882],[@B4-ijerph-13-00882]\]. However, high-density lipoprotein (HDL) has now been shown to play a pivotal role in mediating the transfer of cholesterol from extra hepatic tissues to the liver and reducing the deposition of cholesterol on the artery wall \[[@B5-ijerph-13-00882]\].

Serum HDL-C concentrations are affected by many genetic and environmental factors. The cholesteryl ester transfer protein (CETP) gene located on chromosome 16q21, encodes the key plasma protein that mediates the transfer of esterified cholesterol from HDL to apolipoprotein B-containing particles in exchange for triglycerides \[[@B6-ijerph-13-00882],[@B7-ijerph-13-00882]\]. Mutation of the gene may affect the transcription and expression of CETP, thereby affecting serum HDL-C concentrations \[[@B8-ijerph-13-00882]\]. The *CETP TaqIB* (rs708272) polymorphism is the most common polymorphism in intron 1 of the *CETP* gene and its mutation can affect the concentration as well as activity of plasma CETP, which affected the level of HDL-C \[[@B9-ijerph-13-00882]\]. Recently, though numerous studies have shown a relationship between the *CETP TaqIB* polymorphism in the synthesis of HDL-C and composite ischemic CVD risk, research has remained inconsistent, possibly due to the small sample sizes used in the individual studies.

In 2005, Boekholdt et al. performed a meta-analysis to evaluate the association the *CETP TaqIB* polymorphism in the synthesis of serum HDL-C and CAD risk, and demonstrated that the *CETP TaqIB* variant is associated with HDL-C level and CAD risk in Caucasians \[[@B10-ijerph-13-00882]\]. Li et al. also conducted a meta-analysis to evaluate the association of this variant with CAD in Chinese; however, no relationship between the *CETP TaqIB* polymorphism and CAD was observed \[[@B11-ijerph-13-00882]\]. Cao et al. and Wang et al. performed meta-analysis to evaluate the association the *CETP TaqIB* variant and MI. Their results showed that the *CETP TaqIB-B2* allele protects against the development of MI \[[@B12-ijerph-13-00882],[@B13-ijerph-13-00882]\]. No meta-analysis was found on the association between the *CETP TaqIB* polymorphism and IS. Considering the four meta-analyses above focused only on the association of the *CETP TaqIB* polymorphism with a single atherosclerotic disease and results were controversial in regards to ethnicity (Asians and Caucasians), we performed this meta-analysis to clarify the role of the *CETP TaqIB* polymorphism in the synthesis of HDL-C and the composite ischemic CVD risk.

2. Materials and Methods {#sec2-ijerph-13-00882}
========================

2.1. Literature Search {#sec2dot1-ijerph-13-00882}
----------------------

The protocol was approved by the Institutional Ethics Review Board (IERB) of the First Affiliated Hospital of Shihezi University School of Medicine (IERB No. SHZ2010LL01). Using the standards of the Meta-analysis of Observational Studies in Epidemiology group (MOOSE) \[[@B14-ijerph-13-00882]\] and the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) \[[@B15-ijerph-13-00882]\], searches were performed using the following electronic databases: the Cochrane Library, Embase, PubMed, Web of Science, Springer, China Science and Technology Journal Database (CSTJ), China National Knowledge Infrastructure (CNKI), Google Scholar, and Baidu Library (the last search was conducted on 31 January 2016). Searches were performed using combinations of the following key words: ("cholesteryl ester transfer protein" OR "CETP") and ("variation" OR "variant" OR "mutation" OR "polymorphism" OR "genotype") and ("CAD" OR "coronary artery disease" OR "coronary heart disease" OR "CHD" OR "myocardial infarction" OR "MI" OR "ischemic cardiovascular disease" OR "IS") and ("high-density lipoprotein cholesterol" OR "HDL-C" OR "blood lipid" OR "serum lipid").

2.2. Eligibility Criteria {#sec2dot2-ijerph-13-00882}
-------------------------

The eligibility criteria for the inclusion of articles in the present meta-analysis were the following: (1) The publication evaluated the associations of the *CETP TaqIB* polymorphism with AS or HDL-C level; (2) CAD and MI diagnosis required the result of coronary angiography, and the diagnosis of IS depended on the result of magnetic resonance imaging or computed tomography; (3) published in either Chinese or English; (4) for the composite ischemic CVD association, sufficient published data for calculating odds ratios (ORs) with their 95% confidence intervals (CIs); for HDL-C concentrations association, the population, the mean of HDL-C concentrations, and the standard deviations (SD) by genotype should be available.

2.3. Exclusion Criteria {#sec2dot3-ijerph-13-00882}
-----------------------

The exclusion criteria were as follows: (1) Duplicate publications; (2) incomplete information; (3) insufficient or insignificant statistical data; (4) review articles.

2.4. Data Extraction {#sec2dot4-ijerph-13-00882}
--------------------

Two reviewers (Minghong Yao and Yusong Ding) independently screened full-length articles according to the pre-specified inclusion criteria. For the composite ischemic CVD association, the following information was extracted: name of the first author, year of publication, study population (country, ethnicity), source of controls, case/control sample size, minor allele frequency (MAF), genotype counts in the cases/controls, and evidence of Hardy-Weinberg equilibrium (HWE); for HDL-C concentrations association, name of the first author, year of publication, study population (country, ethnicity), population number, mean of HDL-C concentrations, and their SD by genotype. If key data were not presented in the relevant publications, we tried to obtain them directly from the authors of the relevant studies. When the two reviewers' opinions differed, a third reviewer (ShuXia Guo) was asked to make final decisions regarding the results.

2.5. Quality Assessment for Individual Studies {#sec2dot5-ijerph-13-00882}
----------------------------------------------

The Newcastle-Ottawa Scale (NOS) was used to assessed the methodologic quality of the individual studies by two reviewers (Minghong Yao and Yizhong Yan) \[[@B16-ijerph-13-00882]\]. Each study was evaluated and scored based on three criteria: selection (4 stars), comparability (2 stars), and exposure (3 stars). The NOS point ranges between zero up to nine stars. Any disagreement was resolved by discussion with a third reviewer (Jiaming Liu).

2.6. Data Analysis {#sec2dot6-ijerph-13-00882}
------------------

All statistics were analyzed in Stata 12.0 (StataCorp, College Station, TX, USA). All the tests were two-sided and a *p*-value of less than 0.05 was considered statistically significant. The HWE was assessed using the chi-square test. The strength of associations between the *CETP TaqIB* polymorphism and atherosclerosis were assessed by summary odds ratios (ORs) with 95% confidence intervals (CIs). Pooled ORs were performed for the allele contrasts as followed: (*B1* allele vs. *B2* allele), additive genetic model (*B1B1* vs. *B2B2*), recessive genetic model (*B1B1* vs. *B1B2* + *B2B2*), and dominant genetic model (*B1B1* + *B1B2* vs. *B2B2*), respectively. A pooled standardized mean difference (SMDs) and its 95% CIs were used for the meta-analysis of HDL-C concentrations and the *CETP TaqIB* polymorphism. Heterogeneity across individual studies was calculated using the Cochran's-*Q* statistic and the I^2^ statistic (*p* \< 0.10 and I^2^ \> 50% indicated evidence of heterogeneity) \[[@B17-ijerph-13-00882],[@B18-ijerph-13-00882]\]. With no heterogeneity among studies, the ORs or SMDs estimate of each study was calculated by the fixed effect model (Mantel-Haenszel) \[[@B19-ijerph-13-00882]\]. Otherwise, the random effect model (DerSimonian and Laird) was used \[[@B20-ijerph-13-00882],[@B21-ijerph-13-00882]\]. Subsequently, the Galbraith plot and meta-regression were performed to explore the sources of heterogeneity \[[@B22-ijerph-13-00882]\]. For the composite ischemic CVD association, subgroup analyses were performed based on ethnicity, atherosclerotic diseases, source of controls, and study type; for HDL-C association, subgroup analyses were performed based on ethnicity. Sensitivity analyses were performed based on HWE (studies without HWE were excluded) and sample size (*n* \< 400 were excluded). Potential risk of publication bias was tested by funnel plot and Egger's test.

3. Results {#sec3-ijerph-13-00882}
==========

3.1. Selection and Characteristics of Studies {#sec3dot1-ijerph-13-00882}
---------------------------------------------

The present study met the PRISMA statements (Checklist S1) and MOOSE guidelines ([Table S1](#app1-ijerph-13-00882){ref-type="app"}). The study selection process is detailed in [Figure 1](#ijerph-13-00882-f001){ref-type="fig"}. Through a comprehensive retrieval and evaluation, 45 studies from 44 papers with 20,866 cases and 21,298 controls met the inclusion criteria to assess the association between the *CETP* *TaqIB* polymorphism and the composite ischemic CVD \[[@B23-ijerph-13-00882],[@B24-ijerph-13-00882],[@B25-ijerph-13-00882],[@B26-ijerph-13-00882],[@B27-ijerph-13-00882],[@B28-ijerph-13-00882],[@B29-ijerph-13-00882],[@B30-ijerph-13-00882],[@B31-ijerph-13-00882],[@B32-ijerph-13-00882],[@B33-ijerph-13-00882],[@B34-ijerph-13-00882],[@B35-ijerph-13-00882],[@B36-ijerph-13-00882],[@B37-ijerph-13-00882],[@B38-ijerph-13-00882],[@B39-ijerph-13-00882],[@B40-ijerph-13-00882],[@B41-ijerph-13-00882],[@B42-ijerph-13-00882],[@B43-ijerph-13-00882],[@B44-ijerph-13-00882],[@B45-ijerph-13-00882],[@B46-ijerph-13-00882],[@B47-ijerph-13-00882],[@B48-ijerph-13-00882],[@B49-ijerph-13-00882],[@B50-ijerph-13-00882],[@B51-ijerph-13-00882],[@B52-ijerph-13-00882],[@B53-ijerph-13-00882],[@B54-ijerph-13-00882],[@B55-ijerph-13-00882],[@B56-ijerph-13-00882],[@B57-ijerph-13-00882],[@B58-ijerph-13-00882],[@B59-ijerph-13-00882],[@B60-ijerph-13-00882],[@B61-ijerph-13-00882],[@B62-ijerph-13-00882],[@B63-ijerph-13-00882],[@B64-ijerph-13-00882],[@B65-ijerph-13-00882]\]. The selected study characteristics and data are listed in [Table 1](#ijerph-13-00882-t001){ref-type="table"}. Among these studies, 28 involved CAD \[[@B23-ijerph-13-00882],[@B24-ijerph-13-00882],[@B25-ijerph-13-00882],[@B26-ijerph-13-00882],[@B27-ijerph-13-00882],[@B28-ijerph-13-00882],[@B29-ijerph-13-00882],[@B30-ijerph-13-00882],[@B31-ijerph-13-00882],[@B32-ijerph-13-00882],[@B34-ijerph-13-00882],[@B35-ijerph-13-00882],[@B36-ijerph-13-00882],[@B37-ijerph-13-00882],[@B38-ijerph-13-00882],[@B39-ijerph-13-00882],[@B44-ijerph-13-00882],[@B46-ijerph-13-00882],[@B47-ijerph-13-00882],[@B50-ijerph-13-00882],[@B52-ijerph-13-00882],[@B53-ijerph-13-00882],[@B54-ijerph-13-00882],[@B55-ijerph-13-00882],[@B59-ijerph-13-00882],[@B60-ijerph-13-00882],[@B61-ijerph-13-00882],[@B66-ijerph-13-00882]\], three involved IS \[[@B63-ijerph-13-00882],[@B64-ijerph-13-00882],[@B65-ijerph-13-00882]\], and 14 involved MI \[[@B33-ijerph-13-00882],[@B40-ijerph-13-00882],[@B41-ijerph-13-00882],[@B42-ijerph-13-00882],[@B43-ijerph-13-00882],[@B45-ijerph-13-00882],[@B48-ijerph-13-00882],[@B49-ijerph-13-00882],[@B51-ijerph-13-00882],[@B56-ijerph-13-00882],[@B57-ijerph-13-00882],[@B58-ijerph-13-00882],[@B62-ijerph-13-00882]\]. In addition, there were 26 studies on Caucasians \[[@B23-ijerph-13-00882],[@B24-ijerph-13-00882],[@B25-ijerph-13-00882],[@B27-ijerph-13-00882],[@B30-ijerph-13-00882],[@B38-ijerph-13-00882],[@B39-ijerph-13-00882],[@B40-ijerph-13-00882],[@B41-ijerph-13-00882],[@B42-ijerph-13-00882],[@B43-ijerph-13-00882],[@B44-ijerph-13-00882],[@B45-ijerph-13-00882],[@B47-ijerph-13-00882],[@B48-ijerph-13-00882],[@B50-ijerph-13-00882],[@B51-ijerph-13-00882],[@B53-ijerph-13-00882],[@B56-ijerph-13-00882],[@B57-ijerph-13-00882],[@B58-ijerph-13-00882],[@B60-ijerph-13-00882],[@B62-ijerph-13-00882],[@B63-ijerph-13-00882],[@B64-ijerph-13-00882]\] and 19 studies on Asians \[[@B26-ijerph-13-00882],[@B28-ijerph-13-00882],[@B29-ijerph-13-00882],[@B31-ijerph-13-00882],[@B32-ijerph-13-00882],[@B33-ijerph-13-00882],[@B34-ijerph-13-00882],[@B35-ijerph-13-00882],[@B36-ijerph-13-00882],[@B37-ijerph-13-00882],[@B46-ijerph-13-00882],[@B49-ijerph-13-00882],[@B52-ijerph-13-00882],[@B54-ijerph-13-00882],[@B55-ijerph-13-00882],[@B59-ijerph-13-00882],[@B61-ijerph-13-00882],[@B65-ijerph-13-00882],[@B66-ijerph-13-00882]\]. Controls of 23 studies were hospital-based \[[@B23-ijerph-13-00882],[@B24-ijerph-13-00882],[@B25-ijerph-13-00882],[@B26-ijerph-13-00882],[@B27-ijerph-13-00882],[@B28-ijerph-13-00882],[@B29-ijerph-13-00882],[@B30-ijerph-13-00882],[@B31-ijerph-13-00882],[@B32-ijerph-13-00882],[@B33-ijerph-13-00882],[@B34-ijerph-13-00882],[@B35-ijerph-13-00882],[@B36-ijerph-13-00882],[@B37-ijerph-13-00882],[@B57-ijerph-13-00882],[@B58-ijerph-13-00882],[@B59-ijerph-13-00882],[@B61-ijerph-13-00882],[@B63-ijerph-13-00882],[@B64-ijerph-13-00882],[@B65-ijerph-13-00882],[@B66-ijerph-13-00882]\], while those of the other 22 studies were population-based \[[@B38-ijerph-13-00882],[@B39-ijerph-13-00882],[@B40-ijerph-13-00882],[@B41-ijerph-13-00882],[@B42-ijerph-13-00882],[@B43-ijerph-13-00882],[@B44-ijerph-13-00882],[@B45-ijerph-13-00882],[@B46-ijerph-13-00882],[@B47-ijerph-13-00882],[@B48-ijerph-13-00882],[@B49-ijerph-13-00882],[@B50-ijerph-13-00882],[@B51-ijerph-13-00882],[@B52-ijerph-13-00882],[@B53-ijerph-13-00882],[@B54-ijerph-13-00882],[@B55-ijerph-13-00882],[@B56-ijerph-13-00882],[@B60-ijerph-13-00882],[@B62-ijerph-13-00882]\]. Seven studies did not follow the Hardy-Weinberg equilibrium \[[@B23-ijerph-13-00882],[@B35-ijerph-13-00882],[@B36-ijerph-13-00882],[@B40-ijerph-13-00882],[@B42-ijerph-13-00882],[@B43-ijerph-13-00882],[@B58-ijerph-13-00882]\]. In addition, NOS results showed that the average scores were 6.8.

[Table 2](#ijerph-13-00882-t002){ref-type="table"} describes the characteristics of studies included in the association between the *CETP TaqIB* polymorphism and serum HDL-C concentrations. A total of 28 studies with 23,959 subjects were included in the analysis \[[@B8-ijerph-13-00882],[@B33-ijerph-13-00882],[@B35-ijerph-13-00882],[@B36-ijerph-13-00882],[@B40-ijerph-13-00882],[@B44-ijerph-13-00882],[@B45-ijerph-13-00882],[@B50-ijerph-13-00882],[@B53-ijerph-13-00882],[@B59-ijerph-13-00882],[@B67-ijerph-13-00882],[@B68-ijerph-13-00882],[@B69-ijerph-13-00882],[@B70-ijerph-13-00882],[@B71-ijerph-13-00882],[@B72-ijerph-13-00882],[@B73-ijerph-13-00882],[@B74-ijerph-13-00882],[@B75-ijerph-13-00882],[@B76-ijerph-13-00882],[@B77-ijerph-13-00882],[@B78-ijerph-13-00882],[@B79-ijerph-13-00882],[@B80-ijerph-13-00882],[@B81-ijerph-13-00882],[@B82-ijerph-13-00882],[@B83-ijerph-13-00882],[@B84-ijerph-13-00882],[@B85-ijerph-13-00882]\]. Of these, there were 11 studies on Caucasians \[[@B8-ijerph-13-00882],[@B40-ijerph-13-00882],[@B44-ijerph-13-00882],[@B45-ijerph-13-00882],[@B50-ijerph-13-00882],[@B53-ijerph-13-00882],[@B67-ijerph-13-00882],[@B69-ijerph-13-00882],[@B71-ijerph-13-00882],[@B81-ijerph-13-00882],[@B83-ijerph-13-00882]\] and 17 studies on Asians \[[@B33-ijerph-13-00882],[@B35-ijerph-13-00882],[@B36-ijerph-13-00882],[@B59-ijerph-13-00882],[@B68-ijerph-13-00882],[@B70-ijerph-13-00882],[@B72-ijerph-13-00882],[@B73-ijerph-13-00882],[@B74-ijerph-13-00882],[@B75-ijerph-13-00882],[@B76-ijerph-13-00882],[@B77-ijerph-13-00882],[@B78-ijerph-13-00882],[@B79-ijerph-13-00882],[@B80-ijerph-13-00882],[@B82-ijerph-13-00882],[@B84-ijerph-13-00882],[@B85-ijerph-13-00882]\]. Five studies did not follow the HWE \[[@B35-ijerph-13-00882],[@B72-ijerph-13-00882],[@B74-ijerph-13-00882],[@B76-ijerph-13-00882],[@B77-ijerph-13-00882]\]. Additionally, NOS results showed that the average scores were 6.4.

3.2. Association between the CETP TaqIB Polymorphism and the Composite Ischemic CVD Risk {#sec3dot2-ijerph-13-00882}
----------------------------------------------------------------------------------------

The results of all 45 comparisons showed evidence of a significant association between the *CETP TaqIB* polymorphism and the composite ischemic CVD, suggesting that carriers of allele *TaqIB*-*B1* have a higher risk of the composite ischemic CVD than non-carriers (OR = 1.15, 95% CI = 1.09--1.21) ([Figure 2](#ijerph-13-00882-f002){ref-type="fig"}). The additive genetic model (*B1B1* vs. *B2B2*: OR = 1.26, 95% CI = 1.19--1.34), dominant genetic model (*B1B1* + *B1B2* vs. *B2B2*: OR = 1.20, 95% CI = 1.14--1.27), and recessive genetic model (*B1B1* vs. *B1B2* + *B2B2*: OR = 1.13, 95% CI = 1.08--1.18) were also included in the analysis and results were similar with allele comparison ([Figures S1--S3](#app1-ijerph-13-00882){ref-type="app"}). Subgroup analyses by ethnicity showed significant associations in Asians consistent with that in Caucasians. In addition, significant associations were also found between this variant and susceptibility to the composite ischemic CVD in the population-based group, the hospital-based group, the CAD group, the MI group, the IS group, the case control study group, and the cohort study group, respectively. We also observed the association between *CETP TaqIB*-*B2* polymorphism and the composite ischemic CVD risk where was stronger in the Asian than the Caucasians. The main results of the meta-analysis are shown in [Table 3](#ijerph-13-00882-t003){ref-type="table"}.

3.3. Association between the CETP TaqIB Polymorphism and HDL-C Concentrations {#sec3dot3-ijerph-13-00882}
-----------------------------------------------------------------------------

[Figure 3](#ijerph-13-00882-f003){ref-type="fig"} describes the results of the meta-analysis of the *CETP TaqIB* polymorphism and HDL-C concentrations. Our analysis strongly suggested that carriers of the *B1B1* genotype had lower concentrations of HDL-C than those of the *B2B2* genotype (*B1B1* vs. *B2B2*: SMD = 0.50, 95% CI = 0.36--0.65). We also compared carriers of the *B1B1* genotype with those of the *B1B2* genotype ([Figure S4](#app1-ijerph-13-00882){ref-type="app"}: *B1B1* vs. *B1B2*: SMD = 0.18, 95% CI = 0.10--0.26) and *B1B2* genotype with those of *B2B2* genotype ([Figure S5](#app1-ijerph-13-00882){ref-type="app"}: *B1B2* vs. *B2B2*: SMD = 0.32, 95% CI = 0.21--0.42). Subgroup analyses by ethnicity confirmed that the relationship between the *CETP TaqIB*-*B2* polymorphism and the HDL-C concentration in Asians was less consistent than that in Caucasians ([Figure 2](#ijerph-13-00882-f002){ref-type="fig"}, [Figures S4 and S5](#app1-ijerph-13-00882){ref-type="app"}).

3.4. Sensitivity Analysis {#sec3dot4-ijerph-13-00882}
-------------------------

Sensitivity analysis was performed to determine the robustness of the study results. The included studies were limited to those conforming to HWE and sample size. We performed sensitivity analysis by removing studies without HWE and an *n* \< 400. Overall, the corresponding pooled ORs and SMD were not materially altered for either analysis. Results of the sensitivity analysis suggested that the overall results were relatively robust and credible. The main results of the sensitivity analyses are shown in [Table 3](#ijerph-13-00882-t003){ref-type="table"} and [Figures S6--S11](#app1-ijerph-13-00882){ref-type="app"}.

3.5. Heterogeneity Analysis {#sec3dot5-ijerph-13-00882}
---------------------------

For the relationship between the *CETP TaqIB* polymorphism and the composite ischemic CVD, significant heterogeneity among the available studies were observed in the overall comparisons for the allelic model: *P~Q~* \< 0.001, I^2^ = 57.8%; additive model: *P~Q~* \< 0.001, I^2^ = 55.8%; recessive model: *P~Q~* \< 0.001, I^2^ = 52.0%; and dominant model: *P~Q~* = 0.001, I^2^ = 41.7%. To clarify the sources of heterogeneity, we conducted a meta-regression analysis. The results showed that heterogeneity can be explained by the source of controls for the allelic model: *p* = 0.046, additive model: *p* = 0.025, and dominant model: *p* = 0.039, and ethnicity for the additive model: *p* = 0.048.

For the relationship between the *CETP TaqIB* polymorphism and HDL-C concentrations, significant heterogeneity among the available studies was also observed in the overall comparisons for *B1B1* vs. *B2B2*: *P~Q~* \< 0.001, I^2^ = 90.8%; *B1B1* vs. *B1B2*: *P~Q~* \< 0.001, I^2^ = 79.9%; and *B1B2* vs. *B2B2*: *P~Q~* \< 0.001, I^2^ = 85.1%. Four studies were identified as the main contributors of heterogeneity in the Asian studies \[[@B74-ijerph-13-00882],[@B76-ijerph-13-00882],[@B77-ijerph-13-00882],[@B80-ijerph-13-00882]\] and four studies were identified as the main contributors of heterogeneity in the Caucasian studies \[[@B44-ijerph-13-00882],[@B50-ijerph-13-00882],[@B67-ijerph-13-00882],[@B69-ijerph-13-00882]\] using the Galbraith plot ([Figures S12 and S13](#app1-ijerph-13-00882){ref-type="app"}). [Figures S14--S16](#app1-ijerph-13-00882){ref-type="app"} show the association between the *CETP TaqIB* polymorphism and HDL-C concentrations after exclusion of these outlier studies. However, the significant association between the *CETP* polymorphism and HDL-C concentrations was unchanged both in the Asian subgroup (*B1B1* vs. *B2B2*: SMD = 0.47, 95% CI = 0.36--0.57; *B1B1* vs. *B1B2*: SMD = 0.19, 95% CI = 0.11--0.26; *B1B2* vs. *B2B2*: SMD = 0.28, 95% CI = 0.18--0.37) and Caucasian subgroup (*B1B1* vs. *B2B2*: SMD = 0.35, 95% CI = 0.30--0.40; *B1B1* vs. *B1B2*: SMD = 0.16, 95% CI = 0.12--0.19; *B1B2* vs. *B2B2*: SMD = 0.19, 95% CI = 0.15--0.20).

3.6. Publication Bias {#sec3dot6-ijerph-13-00882}
---------------------

Funnel plots and Egger's test were performed to access the publication bias of literature. For the *CETP* polymorphism and the composite ischemic CVD risk analysis (*B1* vs. *B2*), the shape of the funnel plot ([Figure 4](#ijerph-13-00882-f004){ref-type="fig"}) did not reveal obvious asymmetry, which means no publication bias. This was confirmed by Egger's test (*p* = 0.074). For the *CETP* polymorphism and HDL-C analysis (*B1B1* vs. *B2B2*), neither the shape of the funnel plot ([Figure 5](#ijerph-13-00882-f005){ref-type="fig"}) nor Egger's test (*p* = 0.058) revealed any obvious asymmetry.

4. Discussion {#sec4-ijerph-13-00882}
=============

In the present meta-analysis, a total of 45 studies from 44 papers with 20,866 cases and 21,298 controls, we found that the *TaqIB*-*B2* allele was significantly associated with reduction of composite ischemic CVD both in Caucasians and Asians. Additionally, 28 studies with 23,959 subjects were included in the analysis on the association between the *CETP TaqIB* polymorphism and HDL-C concentrations. According to the results, the *TaqIB*-*B2* allele was significantly associated with a higher level of HDL-C both in Caucasians and Asians. Therefore, it is reasonable to assume that the *CETP TaqIB* polymorphism is influencing HDL-C metabolism to protect against the development of AS. This result suggests that we can use *CETP* inhibitors to prevent and treat dyslipidemia and the composite ischemic CVD. In 2014, Keene et al. performed a meta-analysis to investigate association between the CETP inhibitors and cardiovascular outcomes \[[@B86-ijerph-13-00882]\]. The results show that CETP inhibitors neither increase the serum HDL-C concentration nor reduce the mortality rate of the composite ischemic CVD. It is probably because the trial design or the use of a drug with serious off-target adverse effects. On the other hand, it is well known that the serum HDL-C concentrations affected by multiple environmental and genetic factors. Therefore, the use of CETP inhibitor alone may not be able to reduce the risk of having a clinical atherosclerotic cardiovascular event.

To create a more comprehensive analysis of the association between the *CETP TaqIB* polymorphism and composite ischemic CVD, we performed subgroup analyses based on ethnicity, source of controls, atherosclerotic disease, and study type in the allelic model, additive model, recessive model, and dominant model. Significant associations were found between this variant and susceptibility to composite ischemic CVD in the Caucasian group, Asian group, population-based group, hospital-based group, IS group, CAD group, MI group (except for the recessive model), case control study group, and the subgroup of the cohort study group (except for the recessive model), respectively. For the association between the *CETP TaqIB* polymorphism and HDL-C, we also performed subgroup analysis based on ethnicity in the *B1B1* vs. *B2B2* model, *B1B2* vs. *B2B2* model, and *B1B1* vs. *B1B2* model. Significant associations were found between this variant and serum HDL-C concentrations in both the Caucasian and Asian group. These results further strengthen the conclusion that the *CETP* *TaqIB*-*B2* allele protects against atherosclerosis by influencing HDL-C metabolism both in Asians and Caucasians. We also found that the association between *CETP TaqIB*-*B2* polymorphism and composite ischemic CVD risk was stronger in Asians than Caucasians, but the relationship between the *CETP TaqIB-B2* polymorphism and the HDL-C concentration in Asians was less consistent than that in Caucasians, which can be attributed to different environmental factors, lifestyle, etc.

Considering the influence of small-study effects on the overall results, we performed sensitivity analyses by excluding studies with low sample size or without the HWE. However, the corresponding pooled ORs and SMDs were unchanged in all comparisons, indicating statistically robust results.

Meanwhile, the existence of heterogeneity among the available studies, either for the *CETP TaqIB* polymorphism and composite ischemic CVD or for the *CETP TaqIB* polymorphism and HDL-C may affect the reliability of the results to a large extent. For the relationship between *CETP TaqIB* polymorphism and composite ischemic CVD, the heterogeneity can be explained by the source of controls (hospital controls and population controls) and ethnicity (Asians and Caucasians); for the relationship between *CETP TaqIB* polymorphism and serum HDL-C concentrations, the Galbraith plot was used to detect the source of heterogeneity for Asians and Caucasians. We identified four studies were as the main contributors of heterogeneity for Asians \[[@B74-ijerph-13-00882],[@B76-ijerph-13-00882],[@B77-ijerph-13-00882],[@B80-ijerph-13-00882]\] and four for Caucasians \[[@B44-ijerph-13-00882],[@B50-ijerph-13-00882],[@B67-ijerph-13-00882],[@B69-ijerph-13-00882]\]. The heterogeneity among Asians and Caucasians was effectively removed after excluding these outliers; however, the significant association between the *CETP TaqIB* polymorphism and serum HDL-C concentrations was unchanged. According to these outlier studies, the heterogeneity may be explained by the HWE, sample size, and disease.

There are several potential limitations in our present meta-analysis that should be acknowledged. First, there was significant heterogeneity in our study. Although we used appropriate meta-analytic techniques, we could not completely exclude the influence of the heterogeneity. Second, we may have missed eligible articles reported in other languages because our study only focused on articles published in English and Chinese. Third, the sample sizes of some studies were rather small. In summary, it is well-known that the composite ischemic CVD is affected by multiple environmental and genetic factors. Here, we discussed a single gene polymorphism and its impact on disease; however, several factors remain to be elucidated.

5. Conclusions {#sec5-ijerph-13-00882}
==============

The present meta-analysis shows that the *CETP TaqIB*-*B2* allele is associated with a higher serum HDL-C concentration and plays a protective role in composite ischemic CVD risk both in Asians and in Caucasians. Further investigations with the consideration of genetic and environmental interactions are needed.
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ijerph-13-00882-t001_Table 1

###### 

Characteristics of individual studies included in the meta-analysis of atherosclerosis and the *CETP TaqIB* polymorphism.

  First Author                                        Year   Country           Ethnicity   Disease   Source of Controls   Study Type   Size (Case/Control)   MAF    HWE   Genotypes Distribution (Case/Control)   Score                 
  --------------------------------------------------- ------ ----------------- ----------- --------- -------------------- ------------ --------------------- ------ ----- --------------------------------------- ----------- --------- ---
  Tenkanen et al. \[[@B51-ijerph-13-00882]\]          1991   Finland           Caucasian   MI        PB                   CS           72/115                0.44   Yes   19/33                                   40/65       13/17     8
  Fumeron et al. \[[@B41-ijerph-13-00882]\]           1995   France            Caucasian   MI        PB                   CCS          608/724               0.40   Yes   209/258                                 312/346     87/120    8
  Kuivenhoven et al. \[[@B44-ijerph-13-00882]\]       1998   The Netherlands   Caucasian   CAD       PB                   CS           380/427               0.41   Yes   129/152                                 183/214     68/61     7
  Wu et al. \[[@B33-ijerph-13-00882]\]                2001   China             Asian       MI        HB                   CCS          149/274               0.46   Yes   45/63                                   79/159      25/52     8
  Arca et al. \[[@B38-ijerph-13-00882]\]              2001   Italy             Caucasian   CAD       PB                   CCS          408/180               0.41   Yes   153/67                                  187/77      68/36     8
  Eiriksdottir et al. \[[@B40-ijerph-13-00882]\]      2001   Iceland           Caucasian   MI        PB                   CS           378/745               0.45   No    128/194                                 191/396     59/155    8
  Liu et al. \[[@B45-ijerph-13-00882]\]               2002   USA               Caucasian   MI        PB                   CS           384/384               0.43   Yes   125/122                                 196/193     63/69     8
  Freeman et al. \[[@B56-ijerph-13-00882]\]           2003   UK                Caucasian   MI        PB                   CS           499/1105              0.50   Yes   164/239                                 259/541     76/225    8
  Zhang et al. \[[@B35-ijerph-13-00882]\]             2003   China             Asian       CAD       HB                   CCS          234/164               0.41   No    76/49                                   126/95      32/20     6
  Qin et al. \[[@B29-ijerph-13-00882]\]               2004   China             Asian       CAD       HB                   CCS          249/167               0.41   Yes   81/49                                   131/97      37/21     6
  Wang et al. \[[@B32-ijerph-13-00882]\]              2004   China             Asian       CAD       HB                   CCS          128/247               0.42   Yes   50/72                                   66/123      12/52     6
  Yan et al. \[[@B34-ijerph-13-00882]\]               2004   China             Asian       CAD       HB                   CCS          106/64                0.41   Yes   41/19                                   46/34       19/11     6
  Zhao et al. \[[@B36-ijerph-13-00882]\]              2004   China             Asian       CAD       HB                   CCS          238/203               0.41   No    95/60                                   105/109     38/34     6
  Zheng et al. \[[@B37-ijerph-13-00882]\]             2004   China             Asian       CAD       HB                   CCS          203/100               0.39   Yes   66/33                                   114/55      23/12     6
  Bernard et al. \[[@B43-ijerph-13-00882]\]           2004   UK                Caucasian   MI        PB                   CCS          4442/3273             0.43   No    1477/1100                               2175/1527   790/646   8
  Yilmaz et al. \[[@B42-ijerph-13-00882]\]            2005   Turkey            Caucasian   MI        PB                   CCS          173/111               0.42   No    66/39                                   72/46       35/26     6
  Fidani et al. \[[@B63-ijerph-13-00882]\]            2005   Greek             Caucasian   IS        HB                   CCS          96/100                0.41   Yes   35/34                                   47/45       14/21     6
  Whiting et al. \[[@B53-ijerph-13-00882]\]           2005   USA               Caucasian   CAD       PB                   CS           2392/827              0.42   Yes   792/279                                 1200/377    400/171   8
  Zhang et al. \[[@B54-ijerph-13-00882]\]             2005   China             Asian       CAD       PB                   CCS          88/94                 0.41   Yes   31/32                                   40/50       17/12     6
  Dedoussis et al. \[[@B57-ijerph-13-00882]\]         2007   Greece            Caucasian   MI        HB                   CCS          237/237               0.41   Yes   83/78                                   121/120     33/39     7
  Morgan et al. \[[@B58-ijerph-13-00882]\]            2007   USA               Caucasian   MI        HB                   CCS          805/656               0.44   No    250/224                                 387/297     168/135   6
  Hsieh et al. \[[@B59-ijerph-13-00882]\]             2007   China             Asian       CAD       HB                   CCS          101/264               0.31   Yes   19/23                                   47/111      35/130    5
  Quarta et al. \[[@B64-ijerph-13-00882]\]            2007   Italy             Caucasian   IS        HB                   CCS          215/236               0.43   Yes   79/73                                   105/108     31/55     6
  Muendlein et al. \[[@B27-ijerph-13-00882]\]         2008   Austria           Caucasian   CAD       HB                   CS           332/225               0.40   Yes   125/71                                  162/116     45/38     8
  Rejeb et al. \[[@B30-ijerph-13-00882]\]             2008   Tunisian          Caucasian   CAD       HB                   CS           212/104               0.41   Yes   104/45                                  93/47       15/12     8
  Meiner et al. \[[@B48-ijerph-13-00882]\]            2008   USA               Caucasian   MI        PB                   CCS          550/620               0.45   Yes   173/166                                 282/320     95/134    6
  Wang et al. \[[@B52-ijerph-13-00882]\]              2008   China             Asian       CAD       PB                   CCS          317/298               0.41   Yes   117/99                                  148/146     52/53     6
  Jensen et al. \[[@B62-ijerph-13-00882]\] ^a^        2008   USA               Caucasian   MI        PB                   CS           247/486               0.42   Yes   84/166                                  120/235     42/85     8
  Jensen et al. \[[@B62-ijerph-13-00882]\] ^b^        2008   USA               Caucasian   MI        PB                   CS           259/513               0.41   Yes   89/180                                  126/244     44/89     8
  Padmaja et al. \[[@B28-ijerph-13-00882]\]           2009   Indian            Asian       CAD       HB                   CCS          504/338               0.45   Yes   163/86                                  264/161     77/91     6
  Poduri et al. \[[@B49-ijerph-13-00882]\]            2009   India             Asian       MI        PB                   CCS          265/150               0.41   Yes   117/3                                   107/82      41/35     6
  Tanrikulu-Kucuk et al. \[[@B23-ijerph-13-00882]\]   2010   Turkey            Caucasian   CAD       HB                   CCS          135/112               0.46   No    40/33                                   71/50       24/29     6
  Corella et al. \[[@B39-ijerph-13-00882]\]           2010   Spanish           Caucasian   CAD       PB                   CS           557/1180              0.47   Yes   224/482                                 247/537     86/161    8
  Bhanushali et al. \[[@B66-ijerph-13-00882]\]        2010   Indian            Asian       CAD       HB                   CCS          90/150                0.46   Yes   33/38                                   40/77       17/35     7
  Kolovou et al. \[[@B25-ijerph-13-00882]\]           2011   Greek             Caucasian   CAD       HB                   CCS          374/96                0.42   Yes   126/22                                  202/45      46/29     6
  Zhang et al. \[[@B55-ijerph-13-00882]\]             2011   China             Asian       CAD       PB                   CCS          334/301               0.34   Yes   172/136                                 106/120     56/45     8
  Jiang et al. \[[@B65-ijerph-13-00882]\]             2012   China             Asian       IS        HB                   CCS          220/220               0.29   Yes   130/103                                 72/86       18/31     6
  Tayebi et al. \[[@B61-ijerph-13-00882]\]            2012   Singapore         Asian       CAD       HB                   CCS          659/927               0.45   Yes   228/245                                 322/491     109/191   7
  Lu et al. \[[@B46-ijerph-13-00882]\]                2013   Singapore         Asian       CAD       PB                   CCS          659/927               0.45   Yes   228/245                                 322/491     109/191   8
  Mehlig et al. \[[@B47-ijerph-13-00882]\]            2014   Sweden            Caucasian   CAD       PB                   CCS          618/2921              0.43   Yes   209/938                                 313/1420    96/563    8
  El-Aziz et al. \[[@B50-ijerph-13-00882]\]           2014   Egypt             Caucasian   CAD       PB                   CCS          116/119               0.46   Yes   38/30                                   60/57       18/32     6
  Kaman et al. \[[@B24-ijerph-13-00882]\]             2015   Turkey            Caucasian   CAD       HB                   CCS          210/100               0.44   Yes   44/29                                   81/45       85/26     6
  Liu et al. \[[@B26-ijerph-13-00882]\]               2015   China             Asian       CAD       HB                   CCS          322/108               0.42   Yes   113/40                                  145/47      64/21     6
  Shi et al. \[[@B31-ijerph-13-00882]\]               2015   China             Asian       CAD       HB                   CCS          312/88                0.42   Yes   112/29                                  138/44      62/15     6
  Cyrus et al. \[[@B60-ijerph-13-00882]\]             2016   Saudi Arabia      Caucasian   CAD       PB                   CCS          990/618               0.41   Yes   376/183                                 454/321     160/114   6

a: Nurses' Health Study, b: Health Professionals Follow-up Study, USA: The United States, UK: United Kingdom, CAD: coronary artery disease, MI: myocardial infraction, IS: ischemic stroke, HB: hospital-based, PB: population-based, MAF: minor allele frequencies, HWE: Hardy-Weinberg equilibrium, CS: cohort study, CCS: case control study.
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###### 

Characteristics of individual studies included in the meta-analysis of HDL-C level and the *CETP TaqIB* polymorphism.

  First Author                                     Year   Country           Ethnicity   MAF    HWE   *B1B1*   *B1B2*   *B2B2*   Score                                         
  ------------------------------------------------ ------ ----------------- ----------- ------ ----- -------- -------- -------- ------- ------- ------ ------- ------- ------ ---
  Kuivenhoven et al. \[[@B44-ijerph-13-00882]\]    1998   The Netherlands   Caucasian   0.41   Yes   0.88     0.21     281      0.93    0.21    397    1.01    0.26    129    7
  Gudnason et al. \[[@B67-ijerph-13-00882]\]       1999   Mixed             Caucasian   0.44   Yes   1.13     0.21     237      1.19    0.24    380    1.27    0.22    150    7
  Eiriksdottir et al. \[[@B40-ijerph-13-00882]\]   2001   Iceland           Caucasian   0.45   Yes   1.09     0.31     328      1.12    0.29    596    1.25    0.40    210    8
  Goto et al. \[[@B68-ijerph-13-00882]\]           2001   Japan             Asian       0.43   Yes   1.14     0.28     37       1.23    0.37    47     1.23    0.33    22     6
  Talmud et al. \[[@B8-ijerph-13-00882]\]          2002   UK                Caucasian   0.45   Yes   0.79     0.25     500      0.84    0.25    896    0.90    0.27    317    6
  Liu et al. \[[@B45-ijerph-13-00882]\]            2002   USA               Caucasian   0.43   Yes   1.17     0.28     247      1.24    0.34    389    1.30    0.34    132    8
  Goff et al. \[[@B69-ijerph-13-00882]\]           2002   UK and France     Caucasian   0.47   Yes   1.33     0.40     410      1.29    0.60    889    1.26    0.45    504    7
  Zhang et al. \[[@B35-ijerph-13-00882]\]          2003   China             Asian       0.41   No    1.26     0.22     125      1.30    0.25    221    1.42    0.22    52     6
  Katsunori et al. \[[@B70-ijerph-13-00882]\]      2003   Japan             Asian       0.4    Yes   1.32     0.46     217      1.43    0.57    279    1.59    0.62    95     7
  Zhao et al. \[[@B36-ijerph-13-00882]\]           2004   China             Asian       0.41   Yes   1.19     0.36     155      1.27    0.34    214    1.38    0.39    72     6
  Weitgasser et al. \[[@B71-ijerph-13-00882]\]     2004   Austrian          Caucasian   0.41   Yes   1.49     0.39     358      1.55    0.41    475    1.67    0.41    184    7
  Jiang et al. \[[@B72-ijerph-13-00882]\]          2005   China             Asian       0.37   No    1.16     0.27     49       1.20    0.33    38     1.34    0.29    21     6
  Whiting et al. \[[@B53-ijerph-13-00882]\]        2005   USA               Caucasian   0.42   Yes   0.91     0.33     1071     0.95    0.34    1577   1.00    0.38    571    8
  Huang et al. \[[@B73-ijerph-13-00882]\]          2006   China             Asian       0.40   Yes   1.08     0.29     121      1.13    0.29    163    1.27    0.48    56     6
  Zhang et al. \[[@B74-ijerph-13-00882]\]          2007   China             Asian       0.40   No    1.26     0.31     24       1.34    0.35    20     1.42    0.43    13     6
  Cui et al. \[[@B75-ijerph-13-00882]\]            2007   China             Asian       0.46   Yes   1.44     0.32     17       1.58    0.46    24     1.54    0.36    13     6
  Meena et al. \[[@B76-ijerph-13-00882]\]          2007   Indian            Asian       0.21   No    1.20     0.20     15       1.10    0.10    36     1.10    0.20    106    6
  Hsieh et al. \[[@B59-ijerph-13-00882]\]          2007   China             Asian       0.31   Yes   43.31    10.63    42       43.39   11.09   158    46.24   11.83   165    5
  Zhang et al. \[[@B77-ijerph-13-00882]\]          2008   China             Asian       0.39   No    1.45     0.31     46       1.41    0.23    78     2.03    0.47    16     6
  Wang et al. \[[@B78-ijerph-13-00882]\]           2008   China             Asian       0.44   Yes   1.31     0.38     66       1.39    0.38    98     1.61    0.44    41     6
  Qiu et al. \[[@B79-ijerph-13-00882]\]            2009   China             Asian       0.41   Yes   1.18     0.36     38       1.25    0.33    32     1.28    0.42    21     6
  Tao et al. \[[@B80-ijerph-13-00882]\]            2010   China             Asian       0.41   Yes   0.95     0.19     608      0.96    0.18    939    0.97    0.18    272    6
  Kappelle et al. \[[@B81-ijerph-13-00882]\]       2013   The Netherlands   Caucasian   0.42   Yes   1.28     0.37     2301     1.35    0.40    3233   1.41    0.42    1246   6
  Li et al. \[[@B82-ijerph-13-00882]\]             2014   China             Asian       0.33   Yes   0.99     0.23     82       1.10    0.32    73     1.10    0.27    21     6
  Galati et al. \[[@B83-ijerph-13-00882]\]         2014   Italia            Caucasian   0.42   Yes   1.52     0.45     73       1.45    0.30    106    1.61    0.42    39     7
  El-Aziz et al. \[[@B50-ijerph-13-00882]\]        2014   Egypt             Caucasian   0.49   Yes   0.81     0.11     68       1.14    0.21    117    1.53    0.19    62     6
  Zhai et al. \[[@B84-ijerph-13-00882]\]           2015   China             Asian       0.48   Yes   0.96     0.28     12       1.10    0.25    34     1.12    0.31    14     6
  Jeenduang et al. \[[@B85-ijerph-13-00882]\]      2015   Thailand          Asian       0.37   Yes   1.34     0.32     152      1.35    0.35    169    1.39    0.31    57     6

USA: The United States, UK: United Kingdom, HWE: Hardy-Weinberg equilibrium, SD: standard deviation, HDL-C: High density lipoprotein cholesterol, MAF: minor allele frequencies.
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###### 

Metal-analysis of *CETP TaqIB* polymorphism and risk of atherosclerosis in each subgroup.

  Position                                          Size (Case/Control)   Allele Model        Additive Model   Recessive Model     Dominant Model                                                          
  ------------------------------------------------- --------------------- ------------------- ---------------- ------------------- ---------------- ------------------- -------------- ------------------- --------------
  **Overall analysis**                              20,866/21,298         1.15 (1.09--1.21)   *p* \< 0.001     1.26 (1.19--1.34)   *p* \< 0.001     1.13 (1.08--1.18)   *p* \< 0.001   1.20 (1.14--1.27)   *p* \< 0.001
  *Subgroup analysis based on ethnicity*                                                                                                                                                                   
  Asian                                             5178/5084             1.24 (1.15--1.35)   *p* \< 0.001     1.52 (1.35--1.72)   *p* \< 0.001     1.41 (1.29--1.53)   *p* \< 0.001   1.28 (1.15--1.42)   *p* \< 0.001
  Caucasian                                         15,688/16,214         1.09 (1.04--1.16)   0.001            1.19 (1.11--1.27)   *p* \< 0.001     1.05 (1.00--1.11)   0.041          1.18 (1.11--1.25)   *p* \< 0.001
  *Subgroup analysis based on type of diseases*                                                                                                                                                            
  MI                                                9067/9393             1.10 (1.03--1.19)   0.009            1.18 (1.08--1.29)   *p* \< 0.001     1.05 (0.99--1.12)   0.104          1.17 (1.08--1.26)   *p* \< 0.001
  IS                                                531/556               1.39 (1.17--1.66)   *p* \< 0.001     1.92 (1.33--2.77)   0.001            1.40 (1.09--1.79)   *p* \< 0.001   1.76 (1.25--2.47)   0.001
  CAD                                               11,268/11,349         1.15 (1.08--1.24)   *p* \< 0.001     1.31 (1.21--1.43)   *p* \< 0.001     1.19 (1.12--1.27)   *p* \< 0.001   1.21 (1.13--1.31)   *p* \< 0.001
  *Subgroup analysis based on source of controls*                                                                                                                                                          
  PB                                                14,735/11,618         1.11 (1.05--1.17)   *p* \< 0.001     1.21 (1.13--1.29)   *p* \< 0.001     1.09 (1.04--1.15)   0.001          1.17 (1.10--1.25)   *p* \< 0.001
  HB                                                6131/5180             1.20 (1.10--1.31)   *p* \< 0.001     1.42 (1.26--1.59)   *p* \< 0.001     1.24 (1.14--1.35)   *p* \< 0.001   1.28 (1.16--1.42)   *p* \< 0.001
  *Subgroup analysis based on study type*                                                                                                                                                                  
  CCS                                               15,155/15,187         1.14 (1.10--1.18)   *p* \< 0.001     1.30 (1.21--1.39)   *p* \< 0.001     1.16 (1.11--1.22)   *p* \< 0.001   1.22 (1.15--1.30)   *p* \< 0.001
  CS                                                5711/6111             1.07 (1.01--1.13)   0.023            1.16 (1.03--1.30)   0.012            1.05 (0.97--1.14)   0.277          1.15 (1.04--1.28)   0.007
  **Sensitivity analysis**                                                                                                                                                                                 
  BHWE                                              14,461/16,034         1.16 (1.09--1.23)   *p* \< 0.001     1.33 (1.23--1.42)   *p* \< 0.001     1.18 (1.12--1.24)   *p* \< 0.001   1.24 (1.16--1.32)   *p* \< 0.001
  BS                                                18,902/19,454         1.12 (1.08--1.15)   *p* \< 0.001     1.25 (1.18--1.33)   *p* \< 0.001     1.13 (1.08--1.18)   *p* \< 0.001   1.20 (1.14--1.27)   *p* \< 0.001

CAD: coronary artery disease, MI: myocardial infraction, IS: ischemic stroke, HB: hospital-based, PB: population-based, HWE: Hardy-Weinberg equilibrium, CS: cohort study, CCS: case control study, BHWE: based on Hardy-Weinberg equilibrium (Studies without Hardy-Weinberg equilibrium were excluded), BS: based on sample size (Studies with sample size \< 400 were excluded).

[^1]: These authors contributed equally to this work.
